Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease

recommendations from an expert panel

Rajesh Pahwa, Stuart H. Isaacson, Diego Torres-Russotto, Fatta B. Nahab, Peter M. Lynch, Katya E. Kotschet

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: Evaluation of people with Parkinson’s disease (PD) is often complex due to heterogeneity of symptoms and disease course, including the variability of motor fluctuations and dyskinesia. Routine clinical evaluations may be incomplete, may not accurately capture important symptoms, and may not reflect day-to-day variability. While significant advances have been made in wearable ambulatory continuous objective monitoring (COM) technologies, many clinicians remain uncertain of how to incorporate them in clinical practice, including the value to clinical decision-making. The Personal KinetiGraph™ (PKG) has FDA clearance in the United States, and has recently been used in several clinical studies. Areas covered: An expert group of movement disorders neurologists convened to discuss the clinical utility of the PKG in the routine assessment of people with PD. Based on their experience, the group identified clinical scenarios where objective information gained from review of PKG reports can provide useful information to improve clinical management. Expert commentary: PKG provides clinically meaningful data in patients with PD that can aid the clinician in evaluating patients and optimizing their pharmacologic therapy. Early clinical experience and expert opinion suggest that utilization of COM technologies such as the PKG have the potential to improve medical care in people with PD.

Original languageEnglish (US)
Pages (from-to)669-680
Number of pages12
JournalExpert Review of Neurotherapeutics
Volume18
Issue number8
DOIs
StatePublished - Aug 3 2018

Fingerprint

Parkinson Disease
Technology
Dyskinesias
Movement Disorders
Expert Testimony
Therapeutics

Keywords

  • ambulatory monitoring
  • assessment
  • bradykinesia
  • continuous objective monitoring
  • dyskinesia
  • Parkinson’s disease
  • technology
  • wearable

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease : recommendations from an expert panel. / Pahwa, Rajesh; Isaacson, Stuart H.; Torres-Russotto, Diego; Nahab, Fatta B.; Lynch, Peter M.; Kotschet, Katya E.

In: Expert Review of Neurotherapeutics, Vol. 18, No. 8, 03.08.2018, p. 669-680.

Research output: Contribution to journalReview article

Pahwa, Rajesh ; Isaacson, Stuart H. ; Torres-Russotto, Diego ; Nahab, Fatta B. ; Lynch, Peter M. ; Kotschet, Katya E. / Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease : recommendations from an expert panel. In: Expert Review of Neurotherapeutics. 2018 ; Vol. 18, No. 8. pp. 669-680.
@article{89450b6f071a45aeb74e7abf8343bb3f,
title = "Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease: recommendations from an expert panel",
abstract = "Introduction: Evaluation of people with Parkinson’s disease (PD) is often complex due to heterogeneity of symptoms and disease course, including the variability of motor fluctuations and dyskinesia. Routine clinical evaluations may be incomplete, may not accurately capture important symptoms, and may not reflect day-to-day variability. While significant advances have been made in wearable ambulatory continuous objective monitoring (COM) technologies, many clinicians remain uncertain of how to incorporate them in clinical practice, including the value to clinical decision-making. The Personal KinetiGraph™ (PKG) has FDA clearance in the United States, and has recently been used in several clinical studies. Areas covered: An expert group of movement disorders neurologists convened to discuss the clinical utility of the PKG in the routine assessment of people with PD. Based on their experience, the group identified clinical scenarios where objective information gained from review of PKG reports can provide useful information to improve clinical management. Expert commentary: PKG provides clinically meaningful data in patients with PD that can aid the clinician in evaluating patients and optimizing their pharmacologic therapy. Early clinical experience and expert opinion suggest that utilization of COM technologies such as the PKG have the potential to improve medical care in people with PD.",
keywords = "ambulatory monitoring, assessment, bradykinesia, continuous objective monitoring, dyskinesia, Parkinson’s disease, technology, wearable",
author = "Rajesh Pahwa and Isaacson, {Stuart H.} and Diego Torres-Russotto and Nahab, {Fatta B.} and Lynch, {Peter M.} and Kotschet, {Katya E.}",
year = "2018",
month = "8",
day = "3",
doi = "10.1080/14737175.2018.1503948",
language = "English (US)",
volume = "18",
pages = "669--680",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease

T2 - recommendations from an expert panel

AU - Pahwa, Rajesh

AU - Isaacson, Stuart H.

AU - Torres-Russotto, Diego

AU - Nahab, Fatta B.

AU - Lynch, Peter M.

AU - Kotschet, Katya E.

PY - 2018/8/3

Y1 - 2018/8/3

N2 - Introduction: Evaluation of people with Parkinson’s disease (PD) is often complex due to heterogeneity of symptoms and disease course, including the variability of motor fluctuations and dyskinesia. Routine clinical evaluations may be incomplete, may not accurately capture important symptoms, and may not reflect day-to-day variability. While significant advances have been made in wearable ambulatory continuous objective monitoring (COM) technologies, many clinicians remain uncertain of how to incorporate them in clinical practice, including the value to clinical decision-making. The Personal KinetiGraph™ (PKG) has FDA clearance in the United States, and has recently been used in several clinical studies. Areas covered: An expert group of movement disorders neurologists convened to discuss the clinical utility of the PKG in the routine assessment of people with PD. Based on their experience, the group identified clinical scenarios where objective information gained from review of PKG reports can provide useful information to improve clinical management. Expert commentary: PKG provides clinically meaningful data in patients with PD that can aid the clinician in evaluating patients and optimizing their pharmacologic therapy. Early clinical experience and expert opinion suggest that utilization of COM technologies such as the PKG have the potential to improve medical care in people with PD.

AB - Introduction: Evaluation of people with Parkinson’s disease (PD) is often complex due to heterogeneity of symptoms and disease course, including the variability of motor fluctuations and dyskinesia. Routine clinical evaluations may be incomplete, may not accurately capture important symptoms, and may not reflect day-to-day variability. While significant advances have been made in wearable ambulatory continuous objective monitoring (COM) technologies, many clinicians remain uncertain of how to incorporate them in clinical practice, including the value to clinical decision-making. The Personal KinetiGraph™ (PKG) has FDA clearance in the United States, and has recently been used in several clinical studies. Areas covered: An expert group of movement disorders neurologists convened to discuss the clinical utility of the PKG in the routine assessment of people with PD. Based on their experience, the group identified clinical scenarios where objective information gained from review of PKG reports can provide useful information to improve clinical management. Expert commentary: PKG provides clinically meaningful data in patients with PD that can aid the clinician in evaluating patients and optimizing their pharmacologic therapy. Early clinical experience and expert opinion suggest that utilization of COM technologies such as the PKG have the potential to improve medical care in people with PD.

KW - ambulatory monitoring

KW - assessment

KW - bradykinesia

KW - continuous objective monitoring

KW - dyskinesia

KW - Parkinson’s disease

KW - technology

KW - wearable

UR - http://www.scopus.com/inward/record.url?scp=85052191061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052191061&partnerID=8YFLogxK

U2 - 10.1080/14737175.2018.1503948

DO - 10.1080/14737175.2018.1503948

M3 - Review article

VL - 18

SP - 669

EP - 680

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 8

ER -